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Introduction 
Friedreich’s ataxia is the most common inherited ataxia. 
 
Sources of data 
Literature search using PubMed with keywords Friedreich’s ataxia together with published 
papers known to the authors. 
 
Areas of agreement 
The last decade has seen important advances in our understanding of the pathogenesis of 
disease. In particular, the genetic and epigenetic mechanisms underlying the disease now 
offer promising novel therapeutic targets. 
 
Areas of controversy 
The search for effective disease-modifying agents continues. It remains to be determined 
whether the most effective approach to treatment lies with increasing frataxin protein levels 
or addressing the metabolic consequences of the disease, for example with antioxidants.  
 
Areas timely for developing research 
Management of Freidreich’s ataxia is currently focussed on symptomatic management, de-
livered by the multidisciplinary team. Phase II clinical trials in agents that address the ab-
berrant silencing of the frataxin gene need to be translated into large placebo-controlled 
phase III trials to help establish their therapeutic potential. 
(#4452) 
 Friedreich’s ataxia (FRDA) is an autosomal recessive spinocerebellar ataxia. It is the most 
common inherited ataxia in Europe with prevalence showing large regional differences; 
between 1 in 20 000 in south-west Europe and 1 in 250 000 in the north and east of Eu-
rope1. In the majority of cases the disease is caused by a homozygous GAA triplet repeat 
expansion in the frataxin (FXN) gene, and the shorter repeat expansion length correlates 
with age at onset and disease severity2. The clinical phenotype is broad, but consistently 
involves gait and limb ataxia, dysarthria and loss of lower limb reflexes. Since the original 
description by Nicholaus Friedreich in 1863, our understanding of the genetic aetiology, 
pathophysiology and clinical phenotype has progressed significantly3. Harding’s seminal 
case series provided an important description of FRDA in 115 patient, and the discovery of 
the causative mutation in 1996 has allowed neurologists to further extend and refine our 
understanding of the FRDA phenotype4,5. 
 
Clinical Features 
 
FRDA is a multisystem disorder, affecting both the central and peripheral nervous sys-
tems, the musculoskeletal system, the myocardium and the endocrine pancreas. Whilst 
the “classical” FRDA phenotype varies substantially, gait and limb ataxia, dysarthria and 
loss of lower limb reflexes with deep sensory loss are always detectable. Symptoms tend 
to present between the ages of 10 and 16, and the mixed ataxia is the result of peripheral 
sensory neuropathy, spinocerebellar tract degeneration and cerebellar pathology. Gait 
ataxia develops early and gait is characteristically unsteady, but not overtly broad-based. 
Loss of balance and trunk ataxia necessitate progressive degrees of support, with most 
patients being wheelchair-bound by the third decade. Limb ataxia affects dexterity and co-
ordination such that basic daily activities become increasingly difficult, and nose-finger 
ataxia, upper limb dysdiadochokinesia and impaired heel-shin slide are all common early 
signs. Dysarthria consists of slow, slurred speech which progresses from early in the dis-
ease towards unintelligibility in the advanced stages. Lower limb reflexes are absent, re-
flecting the underlying peripheral neuropathy, and early loss of distal vibration sense re-
flects dorsal root ganglion and dorsal column atrophy. 
 
The later stages of disease are associated with pyramidal weakness, particularly of the 
lower limbs, and distal wasting, which further exacerbates disability. Spasticity has typi-
cally been described in the more advanced stages of the disease, however one study us-
ing biomechanical techniques detected lower limb spasticity in ambulant patients, and in 
those with disease durations of less than 10 years6. Indeed the high prevalence of exten-
sor plantars in the classical phenotype betrays pyramidal involvement early in the disease 
course4. Contractures and painful muscles spasms can develop secondary to spasticity. 
Dysphagia is common and progresses with the disease, and in advanced cases patients 
require modified diets, and eventually nasogastric feeding or gastrostomy7. Common ocu-
lomotor abnormalities in FRDA include fixation instability with frequent square-wave jerks, 
and gaze-evoked nystagmus is less common. Around two thirds of patients exhibit clinical 
or subclinical optic neuropathy, and acuity tends to decline slowly with the disease, to 
blindness in a small number8. A rare but notable exception is apparent in a subpopulation 
of patients who present with rapidly progressive visual loss, similar to that seen in Leber’s 
Hereditary Optic Neuropathy9. Aberrant central auditory processing, detectable as abnor-
mal evoked potentials, is common in FRDA, and the associated temporal distortion of stim-
uli can exacerbate verbal communication difficulties10. In some cases, sensorineural deaf-
ness develops. Urinary urgency and frequency are common complaints, affecting between 
23% and 41%, and bladder overactivity is likely to reflect pyramidal involvement7,11. Bowel 
symptoms, in the form of constipation or incontinence, are common, and are likely related 
to reduced mobility and corticospinal pathology. Sleep-related breathing problems, primar-
ily in the form of obstructive sleep apnoea (OSA) are reported with higher frequency than 
in the normal population, and seems to be associated with increased disease duration and 
severity12.  
 
Common musculoskeletal abnormalities include scoliosis, pes cavus and talipes equino-
varus. Scoliosis is often seen early in the disease, and a signification proportion of patients 
will require surgical correction13. Subtle cognitive deficits have been described involving 
various domains, including executive function, speed and attention, working memory and 
visuospatial reasoning14. A number of small cohort studies have described significant rates 
of depression and anxiety amongst FRDA patients, and whilst these symptoms are consid-
ered by some to reflect a reactive condition in the context of a neurodegenerative disease, 
there is evidence to support a correlation between depression and frontal grey matter vol-
ume loss15,16. 
 
The neurological phenotype of FRDA is the result of diffuse pathological processes affect-
ing various components of the central and peripheral nervous systems. Cerebellar atrophy 
is prominent in the dentate nucleus and its efferent pathways in the superior cerebellar pe-
duncles16. The dorsal root ganglia are smaller than normal, and the large primary sensory 
neurons atrophy early in the disease. These changes lead to an axonal peripheral sensory 
neuropathy and posterior column loss17. Spinal cord diameter is reduced at all levels, but 
atrophy is particularly prominent at the thoracic levels, and loss of corticospinal and spino-
cerebellar tracts is also evident. In line with these macroscopic findings, MRI studies have 
revealed significant grey and white matter loss in the deep cerebellar nuclei and brain-
stem, with the superior cerebellar peduncles showing significant atrophy18. More recent 
volumetric and tractography techniques have extended these findings to include supraten-
torial structures, demonstrating grey matter loss in bilateral precentral gyri and progressive 
white matter changes in the corpus callosum and pyramidal tracts19.  
 
FRDA is strongly associated with a cardiomyopathy, and it is thought that cardiac wall ab-
normalities are present in the majority of patients, though often these will be asympto-
matic. Indeed the ECG reveals repolarisation abnormalities in most cases; typically T-
wave inversion or flattening in lateral or inferior leads, and ST-segment depression or ele-
vation. Common echocardiographic findings include increased end-diastolic septal and 
posterior wall thicknesses, and left ventricular hypertrophy (LVH) which is primarily con-
centric. Longitudinal data suggests that approximately 20% of patients exhibit reduced 
ejection fraction (EF), which tends to decline with age20. One study described two distinct 
cardiac trajectories amongst FRDA patients over a 10-year follow-up period; a large low-
risk group with normal EF at baseline, which declined slightly over time but remained 
within normal range, and a smaller high-risk group associated with a more pronounced 
and progressive decline in EF21. Interestingly, evolution of EF was shown to be independ-
ent of hypertrophy, but correlated with the size of the shorter GAA repeat. The overall pat-
tern of pathology seems to show a slow regression of LVH over time, and a progressive 
increase in left ventricular dilatation. The advanced stages of disease are associated with 
supraventricular tachyarrythmias, most commonly atrial fibrillation (AF) which, if sustained, 
can manifest as palpitations. Furthermore these arrythmias can contribute to worsening 
systolic function and eventually clinical heart failure, which accounts for >50% of deaths in 
FRDA22. Diabetes mellitus (DM) is more prevalent in patients with FRDA when compared 
to age-matched control populations, with estimates varying between 1% and 32%2,7. 
Younger age-at-onset and longer disease duration increase the risk of DM, and it can pre-
sent acutely with ketoacidosis. Evidence suggests that both insulin deficiency, secondary 
to beta-cell apoptosis, and insulin resistance contribute to glucose intolerance and eventu-
ally DM.  
 
Whilst the “classical” phenotype is by far the most prevalent and subsequently most com-
monly studied and described, a significant proportion of cases are described as "atypical", 
most of which are delayed-onset23. Whereas mean age of onset in classical FRDA is be-
tween 10 and 16 years4,7,11, late-onset (LOFA) and very late-onset (VLOFA) Friedreich’s 
ataxia develop after the ages of 25 and 40 years, respectively. Whereas taken together 
these two forms of the disease might represent part of the same phenotypic spectrum, im-
portant distinctions have been described when they are compared to classical FRDA24. 
Delayed-onset cases are characterised by a milder phenotype, slower progression of dis-
ease and a more variable collection of signs and symptoms. Gait and limb ataxia remain 
the most common presenting features, but dysarthria presents late, and spasticity and re-
tained reflexes are encountered more frequently25. Of particular note, non-neurological 
features including scoliosis, pes cavus, cardiomyopathy and diabetes are less frequent 
amongst the delayed-onset cases. As such, morbidity and mortality are less commonly at-
tributable to cardiac complications, although of note the ECG is typically abnormal in most 
cases. A small number of patients will develop symptoms before the age of 5, and such 
cases are classified as early-onset FRDA. These cases are associated with larger GAA 
repeats, a more severe phenotype, faster disease progression and higher incidence of 
cardiac complications23. 
 
FRDA is a progressive disorder, and increases in ataxia rating scales over time have been 
consistently reported. Evidence suggests that those with earlier onset disease suffer a 
more severe and progressive phenotype, although ceiling effects in the more advanced 
stages mean that scale score progression is of limited use over longer disease durations 
(around 20 years). The most common cause of death in FRDA is cardiac dysfunction, 
namely congestive heart failure or arryhthmia, and average age at death was reported as 
36.5 years (range 12-87) in a large retrospective study22. Other causes of death include 
stroke, ischaemic heart disease and pneumonia.  
 
Genetics 
 
The majority of cases of FRDA are associated with a pathological expansion in the non-
coding first intron of the FXN gene. The remaining cases (1-3%) are associated with a 
compound heterozygous expansion with a point mutation or deletion. Expanded trinucleo-
tide tracts containing less than approximately 40 repeats are found in normal chromo-
somes, and the pathological threshold seems to be 70. Triplet numbers in FRDA are most 
commonly between 600 and 900. Heterozygous carriers are healthy, and carrier rate 
amongst Europeans is approximately 1 in 8526.  
 
The intronic GAA expansion silences the FXN gene, resulting in pathologically suppressed 
levels of the frataxin protein. The mechanisms underlying this silencing effect have been 
extensively investigated, in the hope that targeting the initial gene insult might offer a via-
ble strategy for disease modification. Some evidence supports a physical blockade on 
transcription by the GAA repeat, for example in the form of “sticky DNA” triplexes and R-
loops27. These structures could impede the progress of RNA polymerase II through the re-
peats and lead to stalled or aborted transcription. Silencing of the FXN gene might be the 
result of position effect variegation-like effects whereby GAA repeats induce abnormal het-
erochromatisation of nearby genes, rendering them transcriptionally inactive in certain cell 
populations. This effect is thought to arise when the transcriptional balance of euchromatic 
(transcriptionally active) and heterochromatic (transcriptionally inactive) factors is in equi-
librium. Aberrant epigenetic mechanisms including DNA methylation and histone modifica-
tion are thought to tip this balance towards heterochromatin and gene silencing in FRDA. 
DNA methylation is an important mediator of gene expression which is thought to regulate 
the majority of the human genome, and quantitative analyses in peripheral blood mononu-
clear cells from FRDA patients have confirmed abnormally extensive DNA methylation up-
stream of the repeat expansion on the silenced FXN locus28. This methylation is inversely 
correlated with FXN expression and age of onset of disease, suggesting an important role 
in pathogenesis of the disease29. Similar biochemical modifications of histones have been 
shown to modulate the chromatin structure and thus the transcriptional availability of 
genes. High levels of heterochromatic “marks” have been identified in the regions flanking 
the GAA repeat expansion at the FXN locus, and suggest a bidirectionally spreading tran-
scriptional suppression30. Whilst important clarifications still need to be made, particularly 
with regards to the specific chromatin modifiers responsible for silencing the FXN gene 
and the extent of this heterochromatisation, the epigenetic basis of FRDA is providing a 
promising therapeutic approach to promoting frataxin expression. 
 
Frataxin 
 
Frataxin is a small, highly conserved protein, which is encoded in the nucleus, expressed 
in the cytoplasm as a precursor polypeptide, and then imported into the mitochondria. 
Early studies in yeast established a strong association between frataxin and mitochondrial 
iron, describing iron overload and susceptibility to oxidative stress when the frataxin homo-
logue (Yfh1p) is deficient31. In FRDA patients, endomyocardial biopsy analyses have re-
vealed reduced activity of iron-sulphur cluster (ISC) containing subunits of the mitochon-
drial respiratory chain complexes I, II and II, and increased iron deposition32. The ISCs are 
inorganic redox-active protein cofactors that are involved in a variety of cardinal functions 
within the cell, including oxidative phosphorylation, enzyme catalysis and gene regulation. 
 
Bioinformatic studies have provided an important insight into the frataxin interactome, and 
two phylogenetically linked co-occurring genes were originally identified33. The products of 
these two genes in a yeast model, SSQ1 and JAC1, are required for ISC assembly in mito-
chondria, and it has thus been postulated that frataxin plays an integral role in ISC biogen-
esis. Immunoprecipitant and recombinant protein studies have demonstrated a direct inter-
action between human frataxin and a preformed ISC core assembly complex34. The exact 
nature of this interaction however, remains to be established. From a kinetics perspective, 
eukaryotic frataxin increases the rate of ISC formation, and furthermore it facilitates the 
formation of ISCs that are subsequently transferred to cytosolic aconitase to induce a mo-
lecular switch between enzymatic and RNA-binding functions35. Recent evidence suggests 
that human frataxin activates ISC formation by accelerating sulphur transfer on the ISC as-
sembly protein ISCU2, supporting a role for frataxin as an allosteric modulator36.  
 
Whilst the function of frataxin is yet to be characterised completely, its role in the formation 
of ISCs is well supported. Other functional links have been made, in particular with haem 
biosynthesis and ferrochelatase, respiratory chain complex II, and mitochondrial chaper-
ones37. The role of frataxin in these pathways will require further investigation, particularly 
in in vivo models where the metabolic consequences of frataxin deficiency can be eluci-
dated.  
 
Mitochondria 
 
It is essential for us to understand how mitochondrial frataxin deficiency precipitates the 
cellular, tissue and clinical phenotype of FRDA. A strong and consistent link has been 
made between frataxin deficiency, reduced activity of ISC-containing enzymes including 
respiratory chain complexes, and abnormal mitochondrial iron homeostasis. Pathological 
intramitochondrial iron deposition has been reported in yeast knockout models, and cardi-
omyocytes from both conditional knockout mouse models and FRDA patients38. The role 
of intracellular iron accumulation in the neuronal pathology of FRDA is less clear. Evidence 
from X-ray fluorescence and immunohistochemical studies has highlighted an important 
role for glial cells; intracellular ferritin expression is abnormally high in the hyperplastic mi-
croglial populations supporting the dentate nucleus and dorsal root ganglia, and in the lat-
ter, forms part of a constellation of maladaptive changes that might result in impaired 
trophic support of neurons39,40. 
 
The iron-responsive element binding protein (IRP1) is an ISC-containing protein which, in 
conjunction with the structurally similar IRP2, exerts a regulatory effect by binding to iron 
responsive elements (IRE) on the mRNA of proteins involved in iron metabolism. It is pos-
sible that the impaired ISC biosynthesis associated with frataxin deficiency activates IRP1-
mediated cellular iron uptake via IRE-binding and the consequent expression of proteins 
such as transferrin receptor 1. This iron is then translocated to the mitochondria in an at-
tempt to increase ISC synthesis. The lack of frataxin however impedes the ISC-assembly 
complex and so the iron is not utilised, and instead accumulates and is oxidised41. It is 
thought that high levels of free iron increases production of reactive oxygen species, re-
sulting in a greater oxidative stress burden. Evidence from transgenic FRDA mice-derived 
neurons describes a functional imbalance between respiratory chain complexes I and II, 
which drives the formation of free radicals, resulting in glutathione depletion, lipid peroxida-
tion and cell death42. These toxic processes can be rescued by preventing lipid peroxida-
tion and activating antioxidant pathways within the mitochondria43, providing strong evi-
dence for the therapeutic targeting of these processes in FRDA. These oxidative conse-
quences of frataxin deficiency have also been linked to increased mitophagy, impaired cy-
toskeletal dynamics and mitochondrial transport, abnormal calcium homeostasis, and al-
tered lipid metabolism44.  
 
Management 
 
The complex and variable clinical phenotype of FRDA requires a broad multidisciplinary 
approach to management. Whilst significant progress has been made in the search for dis-
ease modifying agents, we are yet to see any therapeutic options that actually halt the pro-
gression of the disease. As such, management currently focuses on symptoms. A compre-
hensive set of consensus clinical management guidelines have recently been published, 
which draw on published evidence and expert opinion to ensure best practice in the deliv-
ery of health services to individuals with FRDA45,46. Of note, early referral to a specialist 
Ataxia Centre will facilitate access to the multi-disciplinary team and ensure an approach 
that is tailored to the individual needs of each patient, with the aim of prolonging independ-
ence and maintaining quality of life. It is essential that newly diagnosed individuals are 
also referred to genetic counselling for discussions on inheritance, implications for family 
members, and the possibility of pre-symptomatic testing. Patient groups offer an invaluable 
source of information and support for patients and their families, e.g. Ataxia UK 
(www.ataxia.org.uk). An overview of the multidisciplinary service pathway is shown in Fig-
ure 1. 
 
Physiotherapy provides an important means of maintaining balance, flexibility, strength 
and accuracy of limb movements, all of which can help to ameliorate the functional conse-
quences of gait and limb ataxia. Furthermore, aerobic exercise training may help to im-
prove weakness and fatigue, which are prevalent and progressive47. Passive stretching by 
the physiotherapist can provide temporary improvement of spasticity, however more pro-
longed muscle lengthening might require splinting, casting, and orthoses48. Spasticity and 
spasm may require pharmacological intervention, including oral options such as baclofen, 
tizanadine, low-dose gabapentin and benzodiazepines, or more advanced techniques in-
cluding botulinum injections, intrathecal baclofen pumps49. Rehabilitation may help coun-
teract the effects of ataxia, weakness and spasticity on function in FRDA patients, by mod-
ifying physiological processes and thereby delaying, maintaining and even improving func-
tional decline. In particular, intensive inpatient rehabilitation programmes have been 
shown to improve function in patients with a variety of neurodegenerative disorders, in-
cluding FRDA50. Occupational therapy allows for the assessment and optimisation of func-
tional status, thereby reducing the impediments to activities of daily living. Specifically, pre-
scription and provision of equipment to maximise independence, home/work modifications, 
retraining of functional skills, and management of educational and vocational issues, are 
all important components of the holistic management approach needed in FRDA. Musculo-
skeletal complications are common in FRDA and scoliosis affects most patients, often with 
onset early in the disease. Indications for surgical correction of scoliosis include a curve 
approaching 50%, and deformity causing functional problems such as poor sitting balance 
and poor head control51,52. Whilst bracing has not been shown to affect prognosis, it may 
help delay surgical correction in young children53. 
 
Problems with speech and swallowing are prevalent in FRDA, and require specialist input 
for assessment, monitoring and treatment. Dysarthria is a primary feature of FRDA, which 
progressively limits communication, and so early and comprehensive assessments are 
fundamental54. Behavioural management strategies encompass a range of measures to 
help facilitate specific communication deficits, and constitute the main approach to speech 
problems55. Measures can include physiotherapy to improve the physical aspect of speech 
generation, compensatory speaking strategies, developing alternative or augmentative 
modes of communication, and managing the communication environment. Patients report-
ing symptoms or showing signs of dysphagia should have a swallowing assessment by a 
speech and language therapist56. The multidisciplinary team can offer environmental modi-
fication and compensatory posture training in order to facilitate safe swallowing57. Dietary 
modification can also be beneficial, and in severe cases nasogastric or gastrostomy feed-
ing may be required for weight maintenance.  
 
Patients should undergo visual screening, in line with national standards, and ophthalmo-
logical input should be sought in the case of visual symptoms. Memantine, acetazolamide 
or clonazepam may be of benefit for treating square wave jerks or ocular flutter58. A com-
prehensive auditory assessment should be completed at time of diagnosis, and should be 
followed-up with annual screening. Tactics involving optimisation of the listening environ-
ment might be beneficial in FRDA, and whereas conventional hearing aids are of little use, 
FM-listening devices may improve hearing and communication59. Bladder symptoms 
should be carefully assessed, involving dipstick analysis for infection, and post-void resid-
ual (PVR) measurement. In cases of overactive bladder, antimuscarinics e.g. oxybutynin, 
tolterodine and solifenacin, can provide symptomatic relief. Alternative options include in-
tradetrusor botulinim toxin A injection, supra-pubic catheterisation, and in the cases of per-
sistently elevated PVR volumes, intermittent self-catheterisation45. Annual reviews should 
also include evaluation of sleep-disordered breathing using the Epworth Sleepiness Scale, 
and patients should be referred for polysomnography if OSA is suspected60. 
 The heart requires special attention in FRDA, as cardiac complications are a common 
cause of morbidity and mortality. An electrocardiogram and echocardiography should be 
performed at diagnosis, and specialist cardiological input should be sought if results are 
abnormal or if cardiac symptoms are present. There are no randomised controlled trials in 
FRDA assessing rhythm- or rate-control in supraventricular tachyarrythmias, and as such it 
is reasonable for clinicians to consider the recommendations included in the 2011 
ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 
Guidelines for the Management of Patients with Atrial Fibrillation61. It is important to note 
that agents with negative inotropic or pro-arrhythmic effects are generally avoided in 
FRDA, especially in the presence of structural heart disease or heart failure. The decision 
on anticoagulation should include thromboembolic risk as defined by the CHA2DS2VASc 
score, and either warfarin or one of the novel oral anticoagulants is recommended. There 
is currently no evidence to support the treatment of patients with normal EF and no symp-
toms or signs of heart failure. A number of studies have investigated the effects of idebe-
none on LV thickness or LV mass index, but findings have been inconsistent62,63. Recom-
mendations from the 2009 Focused Update of the 2005 AHA/ACC Guidelines for the Diag-
nosis and Management of Heart Failure in Adults should be considered when managing 
FRDA patients with heart failure and reduced EF, again in the absence of specific RCT 
data64. Patients should be started on either an angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker, and a beta blocker, and there is a strong evidence base 
demonstrating a reduction in mortality and hospitalisations with these agents64. In cases of 
symptomatic heart failure with reduced ejection fraction, loop diuretics should be pre-
scribed for fluid overload, and mineralocorticoid receptor antagonists can be used in pa-
tients with an EF <35%, and functional status defined as New York Heart Association 
stage III or IV.  In addition to the above options, digoxin can also be considered for symp-
tomatic relief in HF with reduced EF, and it may also be considered a relevant option in pa-
tients with heart failure and AF. Patients with LVEF <35%, QRS duration of >0.12s, and 
sinus rhythm should be considered for device therapy, including cardiac resynchronisation 
therapy, in line with the ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Car-
diac Rhythm Abnormalities65. FRDA patients undergoing major surgery should have a 
thorough assessment of cardiac function as part of their pre-operative review, and peri- 
and post-operative care should be coordinated by a multidisciplinary team. 
 
Annual oral glucose tolerance testing is recommended, and this can be augmented with 
serum HBA1c levels. Patients with impaired glucose tolerance or diabetes should be coun-
selled on the importance of lifestyle changes, in particular dietary changes and physical 
exercise. Metformin should be avoided due to its inhibitory effect on complex I of the elec-
tron transport chain. Despite their antioxidant effects and beneficial effects on frataxin lev-
els in FRDA patient fibroblasts, PPAR-γ agonists, specifically thiazolidinediones, should be 
used with caution due to the risk of water retention and congestive hear failure66. The use 
of incretin analogues, for example exenatide, is endorsed by UK National Guidelines as 
part of specific triple therapy, and interestingly these agents have been shown to prevent 
apoptosis in both pancreatic beta cells and neurons67,68. Their utility in FRDA however re-
mains to be determined. Ultimately, it is typical to require insulin in these patients as sensi-
tisation and lifestyle changes will eventually fail to control serum glucose levels.   
 
Disease modification therapies 
 
Whilst we have yet to see an effective disease modification strategy for FRDA, a number 
of molecules aimed at specific pathological processes have been evaluated in clinical trials 
(Table 1; for individual references see45). Progression of disease is typically measured us-
ing clinical scales, including the Friedreich’s Ataxia Rating Scale (FARS), the International 
Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of 
Ataxia (SARA) which all broadly overlap but do include important distinctions, for example 
the inclusion of functional measures in the FARS. Scores have been shown to correlate 
well with one another, and the SARA exhibits the greatest sensitivity to longitudinal 
change in FRDA, a high construct validity, and requires the smallest sample size for an 
equivalently powered trial69. Earlier clinical trials have focussed on the downstream conse-
quences of frataxin deficieny, specifically the roles roles of oxidative stress and iron accu-
mulation in FRDA, with antioxidant and iron chelation agents being evaluated both as 
monotherapy and in combination, yielding inconsistent results70,71. Other approaches have 
attempted to treat FRDA by restoring frataxin levels. For example, the glycoprotein eryth-
ropoietin has been shown to increase frataxin levels in FRDA models, but clinical trials 
have as yet failed to consistently demonstrate clinical benefit72,73. More recent approaches 
have focussed on the more upstream processes that yield frataxin deficiency. For exam-
ple, histone deacetylase (HDAC) inhibition has emerged as a promising therapeutic strat-
egy that builds on the developing evidence that FRDA is a gene silencing disease with an 
epigenetic basis. A first clinical trial in nicotinamide, a class III HDAC inhibitor, has demon-
strated sustained rises in frataxin levels in FRDA patients74. 
 
Conclusions 
 
FRDA is a complex multisystem disorder caused by a GAA repeat expansion in the first 
intron of the FXN gene. The resulting frataxin deficiency impairs ISC biogenesis, disrupts 
mitochondrial iron homeostasis, and profoundly impacts sensitivity to oxidative stress. 
These processes yield a progressive picture of cell toxicity and death in the heart, the 
nervous systems and the pancreatic beta cells. The resultant phenotype is distinct yet 
highly variable, associated with progressive loss of mobility, cardiac dysfunction and early 
death. A disease modifying treatment is yet to be approved, however various therapeutic 
strategies based on our advancing knowledge of the pathogenesis of FRDA are being 
evaluated. Our understanding of the genetic and epigenetic mechanisms of FXN gene si-
lencing has preceded the use of HDAC inhibitors, and the identification of new pathways 
that upregulate frataxin remain the most promising approach to, and indeed the ultimate 
goal of, treatment of this disease. This fascinating and tragic condition is providing unique 
insights into molecular genetics, bioenergetics and cellular iron dynamics, and it is with 
great anticipation that we hope these insights can be translated into effective treatments to 
halt or even prevent this disease in the future. 
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